Related Experiment Video
Updated: May 29, 2026
08:16
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
ALS clinical trials: do enrolled patients accurately represent the ALS population?
1ALS Centre, Department of Neuroscience, University of Turin, Turin. achio@usa.net
Neurology
|October 7, 2011
Summary
Amyotrophic lateral sclerosis (ALS) clinical trials often enroll younger men with longer diagnostic delays, not fully representing the general ALS patient population. This limits the generalizability of trial findings, highlighting a need for broader patient recruitment strategies.
Area of Science:
- Neurology
- Clinical Trials
- Epidemiology
Background:
- Amyotrophic lateral sclerosis (ALS) clinical trials are crucial for developing new treatments.
- Eligibility criteria in ALS trials may impact the representativeness of enrolled patients.
- Understanding population representativeness is key to the external validity of trial results.
Purpose of the Study:
- To evaluate how eligibility criteria in amyotrophic lateral sclerosis (ALS) clinical trials affect the representativeness of the patient population enrolled.
- To compare patients in ALS clinical trials with a broader ALS patient cohort and a subset meeting trial criteria.
Main Methods:
- Compared patients from 8 ALS clinical trials (2003-2008) with a prospective epidemiologic register (PARALS).
- Analyzed a subset of PARALS patients meeting typical clinical trial inclusion criteria (PARALS-ct).
- Assessed demographic and clinical differences between trial patients and the PARALS cohorts.
Main Results:
- ALS trial patients (n=164) differed significantly from both the overall PARALS cohort (n=813) and the PARALS-ct subset (n=539).
- Trial participants were younger, had longer diagnostic delays, were more likely male, and had a spinal disease onset.
- Tracheostomy-free survival was longer in trial patients (3.9 years) compared to PARALS (2.6 years) and PARALS-ct (2.9 years).
Conclusions:
- Patients enrolled in current ALS clinical trials do not adequately represent the broader ALS population.
- The findings of ALS trials may lack external validity (generalizability) due to biased patient selection.
- Improved patient recruitment strategies, focusing on incident cases, are needed to enhance trial generalizability.
Related Concept Videos
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...